[Bernd Buchmann, Martin Fritsch, Duy Nguyen, Bernd Menzenbach, Ulf Boemer] DE Hohen Neuendorf The invention relates to compounds of general Formula I, the production thereof, and the use thereof as a medicinal product.

[Jorma Hassfeld, Ulrike Roehn, Matthias Friebe, Lutz Lehmann, Tobias Heinrich, Sabine Krause, Damian Brockschnieder, Thomas Dyrks, Andrea Thiele, Ulf Boemer, Ursula Moenning, Markus Berger, Stephan Siegel] DE Berlin This invention relates to compounds (benzothiazoles) suitable for labelling or already labelled by 18F, methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging.

[HARTUNG, Ingo, KETTSCHAU, Georg, THIERAUCH, Karl-Heins, BRIEM, Hans, INCE, Stuart, BOEMER, Ulf, SCHAEFER, Martina, LUECKING, Ulrich] Müllerstrasse 178 13353 Berlin;Wittenauer Strasse 127 13469 Berlin;Mendelstrasse 41 13187 Berlin;Hochwildpfad 45 14169 Berlin;Baumhauser Weg 41a 28279 Bremen;Stephanstrasse 52 10559 Berlin;Leipziger Str. 49 16548 Glienicke/Nordbahn;Ossietzkystr.7 13187 Berlin;Bödiker Strasse 6 10245 Berlin The invention relates to substituted sulfonamido-macrocycles according to the general formula (I): in which R1, R2, R4, R5, A, B, C, L, X, Y, Z, n, and m are as defined in the claims, and salts, N-oxides, or solvates thereof, to pharmaceutical compositions comprising said substituted sulfonamido-macrocycles, to methods of preparing said substituted sulfonamido-macrocycles as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 signalling.

[BUCHMANN, Bernd, NGUYEN, Duy, FRITSCH, Martin, MENZENBACH, Bernd, BOEMER, Ulf] Corporate Patents 13342 Berlin;Erdmannstr. 44 16540 Hohen Neuendorf;Heinrich-Heine-Str. 27 10179 Berlin;Bochumer Str. 22 10555 Berlin;Hufelandweg 9 07743 Jena;Leipziger Str. 49 16548 Glienicke/Nordbahn The invention relates to compounds of general Formula (I), the production thereof, and the use thereof as a medicinal product.

[Ingo Hartung, Stuart Ince, Georg Kettschau, Karl-Heinz Thierauch, Hans Briem, Ulf Boemer] DE Berlin The invention relates to substituted pyrazolopyridines according to the general formula (I): in which A, B, D, E, Ra, R1, R2, R3, R4, R5 and q are as defined in the claims, and salts thereof, to pharmaceutical compositions comprising said substituted pyrazolopyridine compounds, to methods of preparing said substituted pyrazolopyridines, as well as to uses thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 signalling.

[Hermann Kuenzer, Rudolf Knauthe, Monika Lessl, Karl-Heinrich Fritzemeier, Christa Hegele-Hartung, Ulf Boemer, Gerd Mueller, Dirk Kosemund] DE Berlin The invention describes new compounds as pharmaceutical active ingredients, which have in vitro a higher affinity to estrogen receptor preparations from rat prostates than to estrogen receptor preparations from rat uteri and in vivo a preferential action on bone rather than the uterus, their production, their therapeutic use and pharmaceutical dispensing forms that contain the new compounds. The new compounds are 16α- and 16β-hydroxy-estra-1,3,5(10)-estratrienes, which carry additional substituents on the steroid skeleton and can have one or more additional double bonds in the B-, C- and/or D-rings.

[LUECKING, Ulrich, NGUYEN, Duy, VON BONIN, Arne, VON AHSEN, Oliver, KRUEGER, Martin, BRIEM, Hans, KETTSCHAU, Georg, PRIEN, Olaf, MENGEL, Anne, KROLIKIEWICZ, Konrad, BOEMER, Ulf, BOTHE, Ulrich, HARTUNG, Ingo] Müllerstrasse 178 13353 Berlin;Boedikerstr. 6 10245 Berlin;Heinrich-Heine-Strasse 27 10179 Berlin;Rosa Luxemburg Str. 6 a 16548 Glienicke-Nordbahn;Gollanczstr. 139 13465 Berlin;Heerruferweg 7A 13465 Berlin;Baumhauser Weg 41a 28279 Bremen;Mendelstr. 41 13187 Berlin;Luetzenstr. 12 10711 Berlin;Bredowstr. 24 10551 Berlin;Ehrenpreisweg 33 12357 Berlin;Leipziger Str. 49 16548 Glienicke/Nordbahn;Bredowstr. 24 10551 Berlin;Wittenauer Str. 127 13469 Berlin The invention relates to sulfoximine-substituted pyrimidines of the general Formula (I) processes for the preparation thereof and their use as kinase inhibitors for treating for example cancer or inflammation.

[HARTUNG, Ingo, KETTSCHAU, Georg, SCHUMANN, Ingrid, THIERAUCH, Karl-Heinz, BOEMER, Ulf] Müllerstr. 178 13353 Berlin;Wittenauer Str. 127 13469 Berlin;Mendelstr. 41 13187 Berlin;Reichstr. 76 14052 Berlin;Hochwildpfad 45 14169 Berlin;Leipziger Str. 49 16548 Glienicke/Nordbahn The invention relates to 3-H-pyrazolopyridines according to the general formula (I) in which A, B, D, E, Ra, R1, R2, R3, R4, R5 and q are as defined in the claims, and salts, N-oxides, solvates and prodrugs thereof, to pharmaceutical compositions comprising said 3-H-pyrazolopyridine compounds, to methods of preparing said 3-H-pyrazolopyridines, to intermediate compounds useful in said methods, to uses of said intermediate compounds in the preparation of said 3-H-pyrazolopyridines, as well as to uses of said 3-H-pyrazolopyridines for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 signalling.

[HARTUNG, Ingo, KETTSCHAU, Georg, BRIEM, Hans, LUECKING, Ulrich, SCHAEFER, Martina, LIENAU, Philip, BOEMER, Ulf, THIERAUCH, Karl-Heinz] Müllerstrasse 178 13353 Berlin;Wittenauer Str. 127 13469 Berlin;Mendelstrasse 41 13187 Berlin;Baumhauser Weg 41a 28279 Bremen;Bödiker Strasse 6 10245 Berlin;Ossietzkystr.7 13187 Berlin;Pücklerstrasse 33 10997 Berlin;Leipziger Str. 49 16548 Glienicke/Nordbahn;Hochwildpfad 45 14169 Berlin The invention relates to sulfonamido-macrocycles according to the general formula (I): in which R1, R2, R4, R5, R6, A, B, C, L, X, Y, Z, n, and m are as defined in the claims, and salts, N-oxides, or solvates thereof, to pharmaceutical compositions comprising said sulfonamido-macrocycles, to methods of preparing said sulfonamido- macrocycles as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 signalling.

[Ingo Hartung, Hans Briem, Georg Kettschau, Karl-Heinz Thierauch, Ulrich Luecking, Ulf Boemer, Martina Schaefer, Philip Lienau] DE Berlin The invention relates to sulfonamido-macrocycles according to the general formula (I): in which R1, R2, R4, R5, R6, A, B, C, L, X, Y, Z, n, and m are as defined in the claims, and salts, N-oxides, or solvates thereof, to pharmaceutical compositions comprising said sulfonamido-macrocycles, to methods of preparing said sulfonamido-macrocycles as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 signalling.